A new study published in The Lancet journal showed that patients with type 2 diabetes and symptomatic peripheral arterial ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

Ozempic (semaglutide) achieved its main objective with a 13% improvement in maximum walking distance compared to placebo at week 52, translating to an average difference between the groups of ...

Share on Pinterest Ozempic, the active ingredient of which is semaglutide, can also reduce the risk of heart disease, according to research. Steve Christo – Corbis/Corbis via Getty Images ...

Patients with obesity who took semaglutide had lower risk for fractures vs. those who had sleeve gastrectomy. More research is needed to determine the relationship between semaglutide and bone health.

Walking emerges as a potent tool for blood sugar management, particularly beneficial for those with diabetes or prediabetes. Studies reveal that brisk walking significantly lowers diabetes risk ...

A Japanese walking method, discovered in 2007, offers a time-efficient alternative to the 10,000-step goal. Fitness coach Eugene Teo highlights that this 30-minute technique, involving alternating ...

Semaglutide, known primarily for diabetes management and weight reduction, is demonstrating remarkable cardiovascular benefits that begin surprisingly early in treatment and persist long-term.

Semaglutide, sold under brand names like Ozempic, Rybelsus, and Wegovy, belongs to a class of medications called GLP-1 receptor agonists. While FDA-approved for managing diabetes and aiding weight ...

The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide ...

A specific group of nerve cells in the brain stem appears to control how semaglutide affects appetite and weight – without causing nausea. The discovery, made at the University of Gothenburg, could ...